Database : MEDLINE
Search on : methylprednisolone [Words]
References found : 23376 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 2338 go to page                         

  1 / 23376 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29098875
[Au] Autor:Gawarammana I; Buckley NA; Mohamed F; Naser K; Jeganathan K; Ariyananada PL; Wunnapuk K; Dobbins TA; Tomenson JA; Wilks MF; Eddleston M; Dawson AH
[Ad] Address:a Department of Medicine, Faculty of Medicine , University of Peradeniya , Peradeniya , Sri Lanka.
[Ti] Title:High-dose immunosuppression to prevent death after paraquat self-poisoning - a randomised controlled trial.
[So] Source:Clin Toxicol (Phila);:1-7, 2017 Nov 03.
[Is] ISSN:1556-9519
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:CONTEXT: Intentional self-poisoning with the herbicide paraquat has a very high case-fatality and is a major problem in rural Asia and Pacific. OBJECTIVES: We aimed to determine whether the addition of immunosuppression to supportive care offers benefit in resource poor Asian district hospitals. MATERIALS AND METHODS: We performed a randomised placebo-controlled trial comparing immunosuppression (intravenous cyclophosphamide up to 1 g/day for two days and methylprednisolone 1 g/day for three days, and then oral dexamethasone 8 mg three-times-a-day for 14 days) with saline and placebo tablets, in addition to standard care, in patients with acute paraquat self-poisoning admitted to six Sri Lankan hospitals between 1st March 2007 and 15th November 2010. The primary outcome was in-hospital mortality. RESULTS: 299 patients were randomised to receive immunosuppression (147) or saline/placebo (152). There was no significant difference in in-hospital mortality rates between the groups (immunosuppression 78 [53%] vs. placebo 94 [62%] (Chi squared test 2.4, p = .12). There was no difference in mortality at three months between the immunosuppression (101/147 [69%]) and placebo groups (108/152 [71%]); (mortality reduction 2%, 95% CI: -8 to +12%). A Cox model did not support benefit from high-dose immunosuppression but suggested potential benefit from the subsequent two weeks of dexamethasone. CONCLUSIONS: We found no evidence that high dose immunosuppression improves survival in paraquat-poisoned patients. The continuing high mortality means further research on the use of dexamethasone and other potential treatments is urgently needed.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher
[do] DOI:10.1080/15563650.2017.1394465

  2 / 23376 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29095576
[Au] Autor:Rebedew DL
[Ti] Title:Is Central Pontine Myelinolysis Reversible?
[So] Source:WMJ;115(6):326-8, 2016 12.
[Is] ISSN:1098-1861
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Central pontine myelinolysis (CPM) is a rare phenomenon that causes significant morbidity and mortality. Active therapeutic interventions for CPM can have a positive impact on recovery and overall prognosis. This case represents a 34-year-old white man with a chronic history of alcohol abuse who had Parkinsonian symptoms 13 days after rapid correction of his serum sodium in the hospital. Similarly to prior CPM case reports, this patient significantly improved following reinduction of hyponatremia, methylprednisolone, and/or plasmapharesis. This report demonstrates that CPM is potentially reversible when quickly recognized and therapeutic interventions are initiated rapidly.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[St] Status:In-Process

  3 / 23376 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29095118
[Au] Autor:Jin P; Liang X; Wu X; He X; Kuang Y; Hu X
[Ad] Address:a Department of Pharmaceutical Science , Beijing Hospital, National Center of Gerontology , No.1 DaHua Road, Dong Dan, Beijing 100730 , China.
[Ti] Title:Screening and quantification of eighteen glucocorticoid adulterants from herbal pharmaceuticals and health foods by HPLC and confirmed by LC-Q-TOF-MS/MS.
[So] Source:Food Addit Contam Part A Chem Anal Control Expo Risk Assess;, 2017 Nov 02.
[Is] ISSN:1944-0057
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:A procedure for the screening and quantification of eighteen glucocorticoids, i. e. hydrocortisone sodium succinate (HSS), prednisolone (PDL), prednisone (PDS), hydrocortisone (HCS), methylprednisolone (MPS), betamethasone (BTM), dexamethasone (DXM), triamcinolone acetonide (TA), prednisolone acetate (PLA), hydrocortisone acetate (HA), fludrocortisone acetate (FA), prednisone acetate (PA), cortisone acetate (CA), dexamethasone acetate (DA), hydrocortisone butyrate (HB), triamcinolone acetonide acetate (TAA), fluocinonide (FN) and halcinonide (HC), from herbal pharmaceuticals and health foods was established and fully validated. The samples were extracted by methanol and separated by high-performance liquid chromatography (HPLC). The retention times and ultraviolet spectrums were used for the preliminary screening, and the suspected adulterants were then confirmed by liquid chromatography-quadrupole-time of flight mass spectrometry (LC-Q-TOF-MS/MS) and quantified by HPLC. The developed procedure was successfully applied to fourteen herbal samples, and 316.3 µg/g of DA and 13.6 µg/mL of BTM were found in a tablet sample and a spray sample, respectively. To our best knowledge, this is the first report of the simultaneous screening and quantification of these eighteen glucocorticoids from any matrix.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher
[do] DOI:10.1080/19440049.2017.1400184

  4 / 23376 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29093401
[Au] Autor:Watanabe C; Fukui S; Iwamoto N; Shimizu T; Umeda M; Nishino A; Koga T; Kawashiri SY; Ichinose K; Hirai Y; Tamai M; Nakamura H; Origuchi T; Tabata K; Kawakami A
[Ad] Address:Unit of Advanced Preventive Medical Sciences, Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
[Ti] Title:Diffuse Alveolar Hemorrhage Developing Immediately after Immunosuppressive Treatments in a Patient with Granulomatosis with Polyangiitis who had Pulmonary Nodules.
[So] Source:Intern Med;, 2017 Nov 01.
[Is] ISSN:1349-7235
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:A 65-year-old man was diagnosed with granulomatosis with polyangiitis (GPA) based on the detection of high MPO-ANCA, vasculitis and granulomas in a lung biopsy specimen and crescentic glomerulonephritis in a kidney biopsy specimen. Soon after the initiation of intravenous methylprednisolone pulse therapy (mPSL pulse) and intravenous cyclophosphamide pulse therapy (IVCY), the patient experienced cough and hemoptysis. Based on emerging anemia and bilateral diffuse lung consolidation on computed tomography, we judged that diffuse alveolar hemorrhage (DAH) was complicated by GPA. The patient's DAH improved following additional mPSL pulse and IVCY. Physicians should be aware of the possible occurrence of DAH, even when a patient's symptoms improve after mPSL pulse and IVCY.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[St] Status:Publisher
[do] DOI:10.2169/internalmedicine.9188-17

  5 / 23376 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29069021
[Au] Autor:Mydlak A; Soldacki D; Foroncewicz B; Stopa Z; Powala A; Budlewski T; Paczek L; Mucha K
[Ad] Address:aDepartment of Cranio-Maxillofacial Surgery, Oral Surgery and Implantology, Medical University of Warsaw bDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw cDepartment of Pathology, Medical University of Warsaw dNuclear Medicine Unit, Department of Diagnostic Radiology, Central Clinical Hospital Ministry of Internal Affairs eInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
[Ti] Title:Relapsing polychondritis in a liver transplant recipient: A case report.
[So] Source:Medicine (Baltimore);96(43):e8360, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Relapsing polychondritis (RP) is a multisystemic, progressive disease of unknown etiology characterized by recurrent inflammation and progressive cartilage destruction. It can involve all types of cartilage including ears and nose, tracheobronchial tree, joints, and any other tissue rich in proteoglycans such as heart, eyes, and blood vessels. Recurrent chondritis can be life-threatening if the respiratory tract, heart valves, or blood vessels are affected. To date there is no data in the literature on the post solid organ transplantation RP. PATIENT CONCERNS: We present a 59-year-old male liver transplant recipient with primary sclerosing cholangitis who developed RP of the earlobes and nose despite post-transplant immunosuppression. DIAGNOSES: Based on the clinical criteria, scintigraphy and biopsy from the left auricle his condition was diagnosed as RP. INTERVENTIONS: Pulses of methylprednisolone followed by high-dose oral steroids along with azathioprine were administered. OUTCOMES: Such therapy diminished local cartilage inflammation, improved patient's general condition and the laboratory results. Significant loss of ear cartilage and characteristic "saddlenose" were observed after remission of acute symptoms. The control scintigraphy proved very good treatment response. LESSONS: To the best of our knowledge this is the first report on the RP in liver transplant recipient. Based on our patient presentation, we suggest that RP should be suspected in any transplant recipient with cartilage inflammation, and that the Michet's clinical criteria and scintigraphy seem to be the best diagnostic tools for solid organ transplant recipients suspected of RP.
[Mh] MeSH terms primary: Ear Diseases/etiology
Liver Transplantation/adverse effects
Nose Diseases/etiology
Polychondritis, Relapsing/etiology
[Mh] MeSH terms secundary: Cholangitis, Sclerosing/surgery
Ear Cartilage/pathology
Ear Diseases/pathology
Humans
Male
Middle Aged
Nasal Cartilages/pathology
Nose Diseases/pathology
Polychondritis, Relapsing/pathology
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171025
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008360

  6 / 23376 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29044732
[Au] Autor:Yucesan E; Goncu B; Basoglu H; Ozten Kandas N; Ersoy YE; Akbas F; Aysan E
[Ad] Address:Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, Istanbul, Turkey.
[Ti] Title:Fresh tissue parathyroid allotransplantation with short-term immunosuppression: 1-year follow-up.
[So] Source:Clin Transplant;31(11), 2017 Nov.
[Is] ISSN:1399-0012
[Cp] Country of publication:Denmark
[La] Language:eng
[Ab] Abstract:BACKGROUND: Permanent hypoparathyroidism is a serious problem and requires medications indefinitely. Parathyroid allotransplantation (PA) with short-term immunosuppression is definitive choice but long-term results are not clear. METHOD: We performed PA from two donors to two recipients. Both recipients were 39-year-old females. Donors were a 32-year-old female and a 36-year-old male, who both have chronic kidney disease. Routine tests, viral markers, and cross-matches were analyzed individually. The parathyroid glands were resected from the living donors, fragmented quickly in the operation room and injected into the left deltoid muscles of the two recipients. RESULTS: Methylprednisolone was administered on post-PA day one and two. Recipients were discharged from the hospital without complications. Calcium and PTH levels were observed throughout 1 year. We did not observe any complications during the follow-up period. Medications ceased in post-transplantation week 1 for Case 1 and after 1 month for Case 2. CONCLUSION: Fresh tissue PA with short-term immunosuppression appears to be a promising technique that is easy to perform, is cost-effective, has low risk of side effects and minimal complications with compatibility for HLA conditions. A longer follow-up period and more case studies are needed to determine the risks and benefits of this procedure for future cases.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:In-Process
[do] DOI:10.1111/ctr.13086

  7 / 23376 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29030232
[Au] Autor:Chen S; Zheng L; Zhang J; Wu H; Wang N; Tong W; Xu J; Huang L; Zhang Y; Yang Z; Lin G; Wang X; Qin L
[Ad] Address:Musculoskeletal Research Laboratory of Department of Orthopaedics & Traumatology and Innovative Orthopaedic Biomaterial and Drug Translational Research Laboratory of Li Ka Shing Institute of Health, The Chinese University of Hong Kong, Hong Kong, PR China.; Pathology Center, Shanghai General Hos
[Ti] Title:A novel bone targeting delivery system carrying phytomolecule icaritin for prevention of steroid-associated osteonecrosis in rats.
[So] Source:Bone;106:52-60, 2017 Oct 10.
[Is] ISSN:1873-2763
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:One of the effective strategies for prevention of steroid-associated osteonecrosis (SAON) is to inhibit bone resorption and fat formation and promote bone formation at osteonecrotic sensitive skeletal sites. We identified a novel phytomolecule that showed positive effects on osteogenesis, anti-bone resorption and anti-adipogenesis in vitro and also developed a bone-targeting delivery system (BTDS) for in vivo experimental study. The study investigated if our innovative synthesized BTDS carrying this phytomolecule would be able to effectively prevent SAON in a rat model. SAON was induced by combined injections of lipopolysaccharide and methylprednisolone. SAON rats were divided into four groups, one SAON untreated control group and three SAON treatment groups with different types of delivery systems (Asp -liposome-icaritin, liposome-icaritin and Asp -liposome) for two weeks. SAON lesions were identified and osteoclasts activity, osteogenesis and adipogenesis at these sites were evaluated by immunohistochemistry. Ex vitro study was also designed to evaluate the osteogenic and adipogenic potential of the isolated bone marrow stromal cells (BMSCs) via real-time PCR and histochemical staining. Our results showed that as a bone surface-specific BTDS, Asp -liposome-icaritin effectively prevented steroids-treated rats from SAON with significantly decreased osteocytes apoptosis, down-regulated osteoclatsogenesis and up-regulated osteogenesis. However, both liposome-icaritin and Asp -liposome treatment did not show significant efficacy for SAON prevention. In summary, this proof-concept-study showed for the first time that the innovative Asp -liposome-icaritin BTDS was effective for prevention of SAON in terms of bone resorption prevention, adipogenesis suppression, and bone-formation enhancement.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher

  8 / 23376 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28085236
[Au] Autor:Razi CH; Cörüt N; Andiran N
[Ad] Address:Division of Pediatric Allergy, Acibadem, Ankara Private Hospital, Ankara, Turkey.
[Ti] Title:Budesonide reduces hospital admission rates in preschool children with acute wheezing.
[So] Source:Pediatr Pulmonol;52(6):720-728, 2017 Jun.
[Is] ISSN:1099-0496
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The object of this study was to determine whether high doses of inhaled budesonide provide additional benefits to a standardized treatment regimen that includes systemic steroids and salbutamol in preschool patients presented to the emergency department (ED) with acute wheezing attacks. Methods This randomized, double-blind, placebo-controlled, parallel group trial was conducted in children, 6 months-6 years with moderate or severe acute wheezing epizode, as determined based on a pulmonary index score (PIS) of 7-13 points. We compared the addition of budesonide 3 mg versus placebo to standard acute asthma treatment, which included salbutamol and a single 1 mg/kg dose of methylprednisolone given at the beginning of therapy. The primary outcome was differences in hospitalization rates within 4 hr. Secondary outcome was difference in median PIS between treatment groups at 2 hr. Results One hundred patients were enrolled. Cumulative hospitalization rate at 120, 180, and 240 min were 0.72, 0.62, and 0.58 in placebo group; and 0.44, 0.30, and 0.24 in budesonide group. Discharged rate in budesonide group was significantly higher than the placebo group (log-rank = 12.407 ve P < 0.001). Expected mean discharged times were 200.4 (95%CI = 185.3-215.5) min in placebo group and 164.4 (95%CI = 149.4-179.4) min in budesonide group. Median (25-75%) PIS at the 120th min was significantly lower in budesonide group than the placebo group (5 [4-8] vs. 8 [5-9] respectively, P = 0.006). Conclusions The addition of budesonide nebulization may decrease the admission rate of preschool children who have moderate to severe acute wheezing epizodes. Pediatr Pulmonol. 2017;52:720-728. © 2017 Wiley Periodicals, Inc.
[Mh] MeSH terms primary: Bronchodilator Agents/therapeutic use
Budesonide/therapeutic use
Hospitalization/statistics & numerical data
Respiratory Sounds/drug effects
[Mh] MeSH terms secundary: Acute Disease
Albuterol/therapeutic use
Child
Child, Preschool
Double-Blind Method
Drug Therapy, Combination
Emergency Service, Hospital/statistics & numerical data
Female
Humans
Infant
Male
Methylprednisolone/therapeutic use
Nebulizers and Vaporizers
[Pt] Publication type:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Name of substance:0 (Bronchodilator Agents); 51333-22-3 (Budesonide); QF8SVZ843E (Albuterol); X4W7ZR7023 (Methylprednisolone)
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[Js] Journal subset:IM
[Da] Date of entry for processing:170113
[St] Status:MEDLINE
[do] DOI:10.1002/ppul.23667

  9 / 23376 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29089364
[Au] Autor:Ferreira L; Silva J; Garrido S; Bello C; Oliveira D; Simões H; Paiva I; Guimarães J; Ferreira M; Pereira MT; Bettencourt-Silva R; Martins AF; Silva T; Fernandes V; Ferreira M
[Ad] Address:L Ferreira, Endocrinology, Centro Hospitalar do Porto, Porto, 4099-001, Portugal liaferreira00@gmail.com.
[Ti] Title:Primary adrenal insufficiency in adult population: a Portuguese multicentre study by the Adrenal Tumours Study Group.
[So] Source:Endocr Connect;, 2017 Oct 31.
[Is] ISSN:2049-3614
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Primary adrenal insufficiency (PAI) is a rare but severe and potentially life-threatening condition. No previous studies have characterized Portuguese patients with PAI. AIMS: To characterize the clinical presentation, diagnostic workup, treatment and follow-up of Portuguese patients with confirmed PAI. METHODS: This multicentre retrospective study examined PAI patients in 12 Portuguese hospitals. RESULTS: We investigated 278 patients with PAI (55.8% were females), with a mean age of 33.6±19.3 years at diagnosis. The most frequent presenting clinical features were asthenia (60.1%), mucocutaneous hyperpigmentation (55.0%) and weight loss (43.2%); 29.1% of the patients presented with adrenal crisis. Diagnosis was established by high plasma ACTH and low serum cortisol in most patients (43.9%). The most common etiology of PAI was autoimmune adrenalitis (61.0%). There were 38 idiopathic cases. Autoimmune comorbidities were found in 70% of the patients, the most frequent being autoimmune thyroiditis (60.7%) and type 1 diabetes mellitus (17.3%). Seventy-nine percent were treated with hydrocortisone (mean dose 26.3±8.3 mg/day) mostly in three (57.5%) or two (37.4%) daily doses. The remaining patients were treated with prednisolone (10.1%), dexamethasone (6.2%) and methylprednisolone (0.7%); 66.2% were also on fludrocortisone (median dose of 100 g/day). Since diagnosis, 33.5% of patients were hospitalized for disease decompensation. In the last appointment, 17.2% of patients had complaints (7.6% asthenia and 6.5% depression) and 9.7% had electrolyte disturbances. CONCLUSION: This is the first multicentre Portuguese study regarding PAI. The results emphasize the need for standardization in diagnostic tests and aetiological investigation and provide a framework for improving treatment.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171101
[Lr] Last revision date:171101
[St] Status:Publisher

  10 / 23376 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28943538
[Au] Autor:Hosaka T; Nakamagoe K; Tamaoka A
[Ad] Address:Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Japan.
[Ti] Title:Hemolytic Uremic Syndrome-associated Encephalopathy Successfully Treated with Corticosteroids.
[So] Source:Intern Med;56(21):2937-2941, 2017 Nov 01.
[Is] ISSN:1349-7235
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:The encephalopathy that occurs in association with hemolytic uremic syndrome (HUS), which is caused by enterohemorrhagic Escherichia coli (E. coli), has a high mortality rate and patients sometimes present sequelae. We herein describe the case of a 20-year-old woman who developed encephalopathy during the convalescent stage of HUS caused by E.coli O26. Hyperintense lesions were detected in the pons, basal ganglia, and cortex on diffusion-weighted brain MRI. From the onset of HUS encephalopathy, we treated the patient with methylprednisolone (mPSL) pulse therapy alone. Her condition improved, and she did not present sequelae. Our study shows that corticosteroids appear to be effective for the treatment of some patients with HUS encephalopathy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1709
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[St] Status:In-Process
[do] DOI:10.2169/internalmedicine.8341-16


page 1 of 2338 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information